KALA BIO (KALA)

• Market cap: $27.7M
• 1 day: -3.37%
• 5 days: 3.86%
• 1 month: 23.56%
• 3 months: -36.30%
• 6 months: -30.42%
• Year to date: -44.23%
• 1 year: -28.33%
• 5 years: -99.34%
• 10 years: -99.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Employees: 38

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

1% less capital invested

Capital invested by funds: $24M [Q4 2024] → $23.7M (-$285K) [Q1 2025]

7.06% less ownership

Funds ownership: 75.06% [Q4 2024] → 68.0% (-7.06%) [Q1 2025]

12% less funds holding

Funds holding: 33 [Q4 2024] → 29 (-4) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 179% upside
• Avg. target: $13.50 214% upside
• High target: $15 249% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Andreas Argyrides	249% upside $15	Outperform Assumed	2 Jun 2025
HC Wainwright & Co. Yi Chen	179% upside $12	Buy Maintained	23 May 2025